XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Shareholders’ Equity
$ in Thousands
USD ($)
shares
2021 Award
USD ($)
2020 Award
USD ($)
ADDITIONAL PAID-IN CAPITAL
USD ($)
ADDITIONAL PAID-IN CAPITAL
2021 Award
USD ($)
ADDITIONAL PAID-IN CAPITAL
2020 Award
USD ($)
ACCUMULATED OTHER COMPREHENSIVE (LOSS)/ INCOME
USD ($)
ACCUMULATED DEFICIT
USD ($)
Ordinary shares
£ / shares
shares
Ordinary shares
Common stock
USD ($)
shares
Ordinary shares
Common stock
2021 Award
USD ($)
shares
Ordinary shares
Common stock
2020 Award
USD ($)
shares
DEFERRED SHARES
£ / shares
shares
DEFERRED SHARES
Common stock
USD ($)
shares
Beginning balance (in shares) at Dec. 31, 2020 | shares                   35,930,331,000       1,000
Beginning balance at Dec. 31, 2020 $ 196,561     $ 279,480     $ 14,585 $ (97,899)   $ 367       $ 28
Exercise of share options (in shares) | shares                     581,328,000      
Exercise of share options   $ 998     $ 992           $ 6      
Issuance of ordinary shares, net of issuance costs (in shares) | shares                       232,227,000    
Issuance of ordinary shares, net of issuance costs     $ 0     $ (3)           $ 3    
Share-based compensation expense 1,666     1,666                    
Unrealized gain on foreign currency translation 1,988           1,988              
Net loss (12,715)             (12,715)            
Ending balance (in shares) at Mar. 31, 2021 | shares                   36,743,886,000       1,000
Ending balance at Mar. 31, 2021 188,498     282,135     16,573 (110,614)   $ 376       $ 28
Beginning balance (in shares) at Dec. 31, 2020 | shares                   35,930,331,000       1,000
Beginning balance at Dec. 31, 2020 196,561     279,480     14,585 (97,899)   $ 367       $ 28
Exercise of share options (in shares) | shares                   1,188,242   232,227    
Net loss (46,092)                          
Ending balance (in shares) at Sep. 30, 2021 | shares                   41,731,180,000       1,000
Ending balance at Sep. 30, 2021 305,420     441,135     7,817 (143,991)   $ 431       $ 28
Beginning balance (in shares) at Mar. 31, 2021 | shares                   36,743,886,000       1,000
Beginning balance at Mar. 31, 2021 188,498     282,135     16,573 (110,614)   $ 376       $ 28
Exercise of share options (in shares) | shares                   351,449,000        
Exercise of share options 47     43           $ 4        
Issuance of ordinary shares, net of issuance costs (in shares) | shares                   4,600,000,000        
Issuance of ordinary shares, net of issuance costs 154,794     154,743           $ 51        
Share-based compensation expense 1,904     1,904                    
Unrealized gain on foreign currency translation (355)           (355)              
Net loss (17,528)             (17,528)            
Ending balance (in shares) at Jun. 30, 2021 | shares                   41,695,335,000       1,000
Ending balance at Jun. 30, 2021 327,360     438,825     16,218 (128,142)   $ 431       $ 28
Exercise of share options (in shares) | shares                   12,607,000        
Exercise of share options 0                          
Issuance of ordinary shares, net of issuance costs (in shares) | shares                   23,238,000        
Issuance of ordinary shares, net of issuance costs 23     23                    
Share-based compensation expense 2,287     2,287                    
Unrealized gain on foreign currency translation (8,401)           (8,401)              
Net loss (15,849)             (15,849)            
Ending balance (in shares) at Sep. 30, 2021 | shares                   41,731,180,000       1,000
Ending balance at Sep. 30, 2021 305,420     441,135     7,817 (143,991)   $ 431       $ 28
Common stock, par value (in GBP per share) | £ / shares                 £ 0.008       £ 21,921.504  
Beginning balance (in shares) at Dec. 31, 2021 | shares                 42,019,874 42,019,874,000     1 1,000
Beginning balance at Dec. 31, 2021 284,412     444,750     8,840 (169,641)   $ 435       $ 28
Exercise of share options (in shares) | shares                   376,158,000        
Exercise of share options 397     393           $ 4        
Vesting of restricted stock units (in shares) | shares                   68,534,000        
Vesting of restricted stock units 1                 $ 1        
Share-based compensation expense 3,128     3,128                    
Unrealized gain on foreign currency translation (7,193)           (7,193)              
Net loss (21,171)             (21,171)            
Ending balance (in shares) at Mar. 31, 2022 | shares                   42,464,566,000       1,000
Ending balance at Mar. 31, 2022 259,574     448,271     1,647 (190,812)   $ 440       $ 28
Beginning balance (in shares) at Dec. 31, 2021 | shares                 42,019,874 42,019,874,000     1 1,000
Beginning balance at Dec. 31, 2021 $ 284,412     444,750     8,840 (169,641)   $ 435       $ 28
Exercise of share options (in shares) | shares 461,772                 461,772        
Vesting of restricted stock units (in shares) | shares                   72,738        
Net loss $ (60,579)                          
Ending balance (in shares) at Sep. 30, 2022 | shares                 42,554,384 42,554,384,000     1 1,000
Ending balance at Sep. 30, 2022 194,562     454,957     (30,643) (230,220)   $ 440       $ 28
Beginning balance (in shares) at Mar. 31, 2022 | shares                   42,464,566,000       1,000
Beginning balance at Mar. 31, 2022 259,574     448,271     1,647 (190,812)   $ 440       $ 28
Exercise of share options (in shares) | shares                   55,727,000        
Exercise of share options 4     4                    
Vesting of restricted stock units (in shares) | shares                   2,104,000        
Vesting of restricted stock units 0                          
Share-based compensation expense 3,178     3,178                    
Unrealized gain on foreign currency translation (17,134)           (17,134)              
Net loss (21,037)             (21,037)            
Ending balance (in shares) at Jun. 30, 2022 | shares                   42,522,397,000       1,000
Ending balance at Jun. 30, 2022 224,585     451,453     (15,487) (211,849)   $ 440       $ 28
Exercise of share options (in shares) | shares                   29,887,000        
Vesting of restricted stock units (in shares) | shares                   2,100,000        
Share-based compensation expense 3,504     3,504                    
Unrealized gain on foreign currency translation (15,156)           (15,156)              
Net loss (18,371)             (18,371)            
Ending balance (in shares) at Sep. 30, 2022 | shares                 42,554,384 42,554,384,000     1 1,000
Ending balance at Sep. 30, 2022 $ 194,562     $ 454,957     $ (30,643) $ (230,220)   $ 440       $ 28
Common stock, par value (in GBP per share) | £ / shares                 £ 0.008       £ 21,921.504